Shanghai Pharma, SIIC-controlled unit, steps up innovation push via national immunotherapy lab partnership

• Shanghai Industrial Investment Holdings’ affiliate Shanghai Pharma held a 2026 management committee meeting for its national immunotherapy key laboratory.
• The lab, co-built with Shanghai Jiao Tong University, set priorities on staffing, operating mechanisms, evaluation readiness, open innovation, commercialization.
• Shanghai Pharma reaffirmed an innovation-drug-first strategy, aiming to accelerate translation of Shanghai research into products and industrial scale-up.
• The lab reported 20-plus immunology mechanisms or targets, three first-in-class biomarkers, an early AI drug-discovery platform, two national tasks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Industrial Investment Holdings Co Ltd published the original content used to generate this news brief on August 24, 2026, and is solely responsible for the information contained therein.